Proactiveinvestors recommends
Additional Information
Market: OTCBB
Sector: Pharmaceuticals
EPIC: ACCP
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Access Pharmaceuticals
accesspharma.com/index.shtml

Access Pharmaceuticals (ACCP:  OTCBB) is an emerging specialty pharma company developing and commercializing propriety products for the treatment and supportive care of cancer patients.  MuGard, its FDA approved treatment for oral mucositis, is commercially launched in Europe, and will launch in the US and Asian in 1Q 2010.  ProLindac, which is in pivotal clinical trials, is a new and improved version of Sanofi-Aventis’ Eloxatin, a DACH Platinum chemotherapeutic.  Thiarabine is in human trials for the treatment of leukemias and lymphomas.  Lastly, ACCP has collaborations in the areas of oral insulin and oral human growth hormone, using it’s proprietary Cobalamin based oral drug delivery platform.

Full Access Pharmaceuticals profile here
Pdf

Access Pharmaceuticals reports positive clinical feedback for MuGard

9th Feb 2011, 12:01 pm by Deborah Sterescu
Market for treatment of oral mucositis, a side effect of cancer therapy, estimated to be in excess of $1bn worldwide Market for treatment of oral mucositis, a side effect of cancer therapy, estimated to be in excess of $1bn worldwide

Access Pharmaceuticals (OTCBB: ACCP) reported Wednesday it has been receiving positive clinical feedback for its MuGard treatment, used as supportive care for patients undergoing cancer therapy.

Specifically, MuGard is an oral rinse that treats leasions of the mouth for patients with oral mucositis, a side effect of radiation and chemotherapy. The product received marketing clearance in the US and in Europe.

Dallas, Texas-based Access said today that it received feedback from a prescribing nurse at a southwest oncology practice, where MuGard was introduced more than three months ago. Since then, the oral rinse has been incorporated into the regimens of approximately 80 cancer patients.

According to the company, the respective nurse highlighted that "...MuGard has worked on all but one patient... [and]...has made a huge impact in our practice."

"It's the first product for oral mucositis we've had to give them that has made a difference."

The detailed feedback can be viewed under the "testimonials" section of the MuGard website, www.MuGard.com, or by clicking on the following link, http://www.mugard.com/testimonials/.

Up to 40% of all patients receiving chemotherapy and radiotherapy develop moderate to severe mucositis. The market for treatment is estimated to be in excess of $1 billion worldwide.

Aside from MuGard, Access' products include ProLindac, which is in phase 2 clinical testing for patients with ovarian cancer.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.